Donald Graneto, MD
Family Medicine · Dallas, TXNPI 1669672481
Payments from drug & device makers
Across 509 payments — averaging $25.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$5K
- Gilead$3K
- Merck$1K
- Novo Nordisk$742
- Johnson & Johnson$631
- Theratechnologies Inc.$353
- plus $2K from 29 others
What the payments were for
- Food & beverage$12,897100%
- Education$520%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 172 | $4,536 |
| Gilead | 88 | $2,987 |
| Merck | 49 | $1,260 |
| Novo Nordisk | 33 | $742 |
| Johnson & Johnson(2 entities) | 37 | $631 |
| Theratechnologies Inc. | 19 | $353 |
| Lilly USA, LLC | 17 | $308 |
| EMD Serono, Inc. | 13 | $279 |
| Amarin Pharma, Inc. | 11 | $246 |
| Pfizer | 10 | $185 |
| Antares Pharma, Inc. | 11 | $168 |
| AbbVie(2 entities) | 9 | $159 |
| AstraZeneca | 5 | $147 |
| Janssen Products, LP | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $121 |
| Amgen | 4 | $104 |
| GSK | 5 | $74 |
| Hologic Sales And Service, LLC | 1 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Medtronic | 1 | $52 |
| Lundbeck LLC | 2 | $45 |
| Janssen Scientific Affairs, LLC | 2 | $40 |
| Eisai Inc. | 2 | $34 |
| Shire North American Group Inc | 2 | $30 |
| Halozyme Inc | 1 | $22 |
| Abbott | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $20 |
| Napo Pharmaceuticals Inc | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Dynavax Technologies Corporation | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,949 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 104 | $420,933 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 67 | $369,371 |
| DovatoDolutegravir Sodium/Lamivudine | 108 | $357,104 |
| DescovyEmtricitabine/Tenofov Alafenam | 59 | $133,787 |
| TivicayDolutegravir Sodium | 47 | $126,800 |
| PrezcobixDarunavir/Cobicistat | 48 | $121,699 |
| OzempicSemaglutide | 78 | $99,821 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 19 | $73,653 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $42,784 |
| JardianceEmpagliflozin | 20 | $34,327 |
| MounjaroTirzepatide | 22 | $27,210 |
| Repatha SureclickEvolocumab | 36 | $21,747 |
| VascepaIcosapent Ethyl | 21 | $21,627 |
| FarxigaDapagliflozin Propanediol | 14 | $13,287 |
| Testosterone | 23 | $12,595 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Tivicay, Triumeq | $4,536 | $557,557174 claims |
| GileadBiktarvy, Descovy | $2,987 | $554,720163 claims |
| Janssen Products, LPSymtuza | $125 | $369,37167 claims |
| Johnson & JohnsonPrezcobix | $631 | $121,69948 claims |
| Novo NordiskOzempic | $742 | $99,82178 claims |
| Lilly USA, LLCMounjaro | $308 | $27,21022 claims |
| AstraZenecaFarxiga | $147 | $13,28714 claims |
| Antares Pharma, Inc.Xyosted | $168 | $6,61411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Dallas
- Thomas KingDallas$12M
- Jennifer ZonDallas$5.9M
- Chrisette DharmagunaratneDallas$5.6M
- Michele ReynoldsDallas$3.8M
- Shiwali RaiDallas$2.8M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.